AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34062314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation performed 1 year or less before endoscopy
Number of subjects: 100
Study 34062314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation performed more than 1 year before endoscopy
Number of subjects: 100
Study 34062314 — intervention group
Group type: COMPARATOR
Intervention: Nondilated patients
Number of subjects: 100
Study 34062626 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish version of the Pain Self-Efficacy Questionnaire (PSEQ-DK)
Number of subjects: 92
Study 34063194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by the Five Facet Mindfulness Questionnaire)
Number of subjects: 117
Study 34063194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreactivity (a component of mindfulness)
Number of subjects: 117
Study 34063194 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious presence and nonjudgment (components of mindfulness)
Number of subjects: 117
Study 34064209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal adjustments combined with physical therapy (chiro + PT)
Number of subjects: 63
Study 34064209 — intervention group
Group type: COMPARATOR
Intervention: Sham chiropractic with physical therapy (sham + PT)
Number of subjects: 63
Study 34064657 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 3271
Study 34064657 — intervention group
Group type: COMPARATOR
Intervention: Participants without periodontitis or PAOD
Number of subjects: 3271
Study 34065252 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL-C levels
Number of subjects: 1689
Study 34065252 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic and lifestyle factors
Number of subjects: 1689
Study 34065252 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of cancer
Number of subjects: 1689
Study 34065517 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Psychotherapeutic Group Treatment (IPGT)
Number of subjects: 159
Study 34065517 — intervention group
Group type: COMPARATOR
Intervention: Self-Help Groups (SHG)
Number of subjects: 159
Study 34065523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program (12 weeks supervised by family caregivers)
Number of subjects: 62
Study 34065523 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative rehabilitation (control group)
Number of subjects: 62
Study 34065523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program
Number of subjects: 62
Study 34065642 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI)
Number of subjects: 870
Study 34065642 — intervention group
Group type: COMPARATOR
Intervention: No contrast-associated acute kidney injury (No CA-AKI)
Number of subjects: 870
Study 34065859 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax/S63845 combination therapy
Number of subjects: 0
Study 34065859 — intervention group
Group type: EXPERIMENTAL
Intervention: NOXA expression
Number of subjects: 0
Study 34065859 — intervention group
Group type: EXPERIMENTAL
Intervention: MCL-1 BH3 mimetic, S63845
Number of subjects: 0
Study 34066300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifluorid 10
Number of subjects: 340
Study 34066300 — intervention group
Group type: EXPERIMENTAL
Intervention: Futurabond U
Number of subjects: 340
Study 34066473 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk (MOM)
Number of subjects: 117
Study 34066473 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM)
Number of subjects: 117
Study 34066473 — intervention group
Group type: COMPARATOR
Intervention: Formula
Number of subjects: 117
Study 34066713 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34 Stem Cell Therapy
Number of subjects: 3000000
Study 34066713 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 3000000
Study 34066948 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 1: Low transactional sex and high power
Number of subjects: 322
Study 34066948 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 2: Moderate transactional sex and moderate power
Number of subjects: 322
Study 34066948 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 3: High transactional sex and low power
Number of subjects: 322
Study 34066948 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 4: Very high transactional sex and very low power
Number of subjects: 322
Study 34067039 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid continuation (CSC)
Number of subjects: 105
Study 34067039 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid withdrawal
Number of subjects: 105
Study 34067093 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoupling protein 1 (UCP1), specific dosage and duration not mentioned
Number of subjects: 0
Study 34068534 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured home-based exercise (SHB) program
Number of subjects: 60
Study 34068534 — intervention group
Group type: COMPARATOR
Intervention: Walking advice (Control)
Number of subjects: 60
Study 34069594 — intervention group
Group type: EXPERIMENTAL
Intervention: Milan criteria period (MilanCP)
Number of subjects: 523
Study 34069594 — intervention group
Group type: COMPARATOR
Intervention: AFP model period (AFPscP)
Number of subjects: 523
Study 34069594 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP model
Number of subjects: 523
Study 34069594 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft allocation policy
Number of subjects: 523
Study 34070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab combined with Durvalumab
Number of subjects: 18
Study 34070172 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacytidine (AZA)
Number of subjects: 0
Study 34070172 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine plus low-dose cytarabine (FLUGA)
Number of subjects: 0
Study 34070561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (starting dose 100 mg/sm, maximum 300 mg/sm)
Number of subjects: 0
Study 34070561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (starting dose 15 mg/sm)
Number of subjects: 0
Study 34070561 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (starting dose 3 mg/sm)
Number of subjects: 0
Study 34070561 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC (Pressurized Intra-Peritoneal Aerosol Chemotherapy)
Number of subjects: 0
Study 34071188 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) as first-line therapy for HCC
Number of subjects: 0
Study 34071188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-engineered NK cells and T cells
Number of subjects: 0
Study 34071908 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid maintenance therapy
Number of subjects: 0
Study 34071908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34071967 — intervention group
Group type: EXPERIMENTAL
Intervention: Samsung Health application
Number of subjects: 0
Study 34071967 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG M-Trace Base II application
Number of subjects: 0
Study 34072165 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to Alzheimer's Disease (AD)
Number of subjects: 680
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Incontinence (UI) prevalence in female athletes
Number of subjects: 63
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-distance running
Number of subjects: 63
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and years of sport practice
Number of subjects: 63
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbent pads usage
Number of subjects: 63
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on sporting life
Number of subjects: 63
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for UI
Number of subjects: 63
Study 34073782 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tract infections or candidiasis
Number of subjects: 63
Study 34074313 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 120
Study 34074827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 432202
Study 34074827 — intervention group
Group type: COMPARATOR
Intervention: No Sedation
Number of subjects: 432202
Study 34074856 — intervention group
Group type: COMPARATOR
Intervention: HBO2 (Hyperbaric Oxygen Therapy) within 6 hours
Number of subjects: 706
Study 34074889 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (e.g., dapagliflozin)
Number of subjects: 0
Study 34074889 — intervention group
Group type: COMPARATOR
Intervention: CREDENCE trial (control group with DKD)
Number of subjects: 0
Study 34075392 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI score at 16-22 weeks
Number of subjects: 1887
Study 34075392 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH score at 8-13 weeks
Number of subjects: 1887
Study 34075392 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH score at 16-22 weeks
Number of subjects: 1887
Study 34075392 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI score at 24-29 weeks
Number of subjects: 1887
Study 34075392 — intervention group
Group type: EXPERIMENTAL
Intervention: AMED score at 8-13 weeks
Number of subjects: 1887
Study 34075392 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH score at 24-29 weeks
Number of subjects: 1887
Study 34076556 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB vaccine
Number of subjects: 0
Study 34076745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-labeled IL-2 PET imaging
Number of subjects: 0
Study 34076831 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation group (tandem high-dose chemotherapy (HDCT) and craniospinal irradiation (CSI))
Number of subjects: 49
Study 34076831 — intervention group
Group type: COMPARATOR
Intervention: Switched group (modified treatment)
Number of subjects: 49
Study 34076831 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable disease (SD) group
Number of subjects: 49
Study 34076831 — intervention group
Group type: COMPARATOR
Intervention: Progressive disease (PD) group
Number of subjects: 49
Study 34077628 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE)
Number of subjects: 11440
Study 34077678 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring of the lymphatic architecture and transport through near-infrared fluorescence lymphatic imaging
Number of subjects: 0
Study 34078022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg for 24 weeks, increased to 40 mg if necessary after 12 weeks
Number of subjects: 62
Study 34078106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy in patients with ASPECTS of 0 to 5
Number of subjects: 763
Study 34078106 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy in patients with ASPECTS of 6 to 10
Number of subjects: 763
Study 34078106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients <65 years of age with ASPECTS 0-5
Number of subjects: 763
Study 34078203 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care-based delivery model with direct access to a diabetes educator
Number of subjects: 4894
Study 34078203 — intervention group
Group type: COMPARATOR
Intervention: Usual care with referrals to traditional hospital-based outpatient DSMES programs
Number of subjects: 4894
Study 34078234 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of interferon-λ 4 (IFN-λ4)
Number of subjects: 279
Study 34078234 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, absent/mild steatosis, low viral load
Number of subjects: 279
Study 34078259 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 641
Study 34078260 — intervention group
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol (1 g/day) for 1 month
Number of subjects: 10
Study 34078260 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 10
Study 34078306 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Number of subjects: 0
Study 34078306 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic family involvement and support scale
Number of subjects: 0
Study 34078306 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation fidelity assessment scale
Number of subjects: 0
Study 34078306 — intervention group
Group type: EXPERIMENTAL
Intervention: General organizational index scale
Number of subjects: 0
Study 34078399 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care ultrasound screening for DVT performed by ICU residents
Number of subjects: 90
Study 34078399 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care ultrasound screening for DVT
Number of subjects: 90
Study 34078399 — intervention group
Group type: COMPARATOR
Intervention: Patients with VTE (n=8)
Number of subjects: 90
Study 34078435 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B > 0.10 μg/L
Number of subjects: 566
Study 34078435 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B < 0.10 μg/L
Number of subjects: 566
Study 34078435 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 566
Study 34078477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuneiform nucleus deep brain stimulation (CnF DBS)
Number of subjects: 4
Study 34078485 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma severity as measured by the Childhood Trauma Questionnaire
Number of subjects: 554
Study 34078485 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals without a psychiatric history
Number of subjects: 554
Study 34078581 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV in bicuspid AS
Number of subjects: 107
Study 34078581 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN 3 THV in tricuspid AS
Number of subjects: 107
Study 34078652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Number of subjects: 93
Study 34078651 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab), a humanized IgG4 anti-Clever-1 antibody
Number of subjects: 0
Study 34078651 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 34078915 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 6
Study 34079458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Number of subjects: 0
Study 34079488 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibly-Dosed Intensive Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 34079488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34080074 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP optimization using electrical impedance tomography (EIT)
Number of subjects: 20
Study 34080074 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation according to ARDS Network recommendations
Number of subjects: 20
Study 34080123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (fed arm)
Number of subjects: 239
Study 34080123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (fasting arm)
Number of subjects: 239
Study 34080123 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide (reference arm)
Number of subjects: 239
Study 34080123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (dosing conditions trial)
Number of subjects: 239
Study 34080309 — intervention group
Group type: EXPERIMENTAL
Intervention: Milademetan with strong CYP3A inhibitor (itraconazole or posaconazole)
Number of subjects: 0
Study 34080441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture administered twice per week for 5 weeks, 30 min per session.
Number of subjects: 6
Study 34080441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture protocol acceptability questionnaire.
Number of subjects: 6
Study 34080708 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem administered by a 4-h infusion of 1 g q6h
Number of subjects: 50
Study 34080708 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 50
Study 34080708 — intervention group
Group type: COMPARATOR
Intervention: ECMO support
Number of subjects: 50
Study 34080708 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage of imipenem
Number of subjects: 50
Study 34080708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage regimens in patients with renal impairment
Number of subjects: 50
Study 34080792 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy (DA) prior to drug coated balloon (DCB) angioplasty
Number of subjects: 102
Study 34081015 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health monitoring (HHM) technology for 60 days post-discharge.
Number of subjects: 70
Study 34081059 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 30 min·d-1 of ST with 30 min·d-1 of MVPA
Number of subjects: 228
Study 34081059 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 30 min·d-1 of ST with 30 min·d-1 of LPA
Number of subjects: 228
Study 34081125 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34081353 — intervention group
Group type: EXPERIMENTAL
Intervention: PICU admission
Number of subjects: 110
Study 34081353 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with parents
Number of subjects: 110
Study 34082006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (daily oral for 12 months)
Number of subjects: 126
Study 34082024 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (PARP inhibitor)
Number of subjects: 10
Study 34082024 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib + AZD6738 (ATR inhibitor)
Number of subjects: 10
Study 34082024 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib + ceralasertib (ATR inhibitor)
Number of subjects: 10
Study 34082253 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire assessment before admission and after one year
Number of subjects: 797
Study 34082253 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews with 19 purposively selected patients
Number of subjects: 797
Study 34082253 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic coding using the PROMIS framework
Number of subjects: 797
Study 34082643 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (GSK's seasonal inactivated influenza vaccines)
Number of subjects: 507
Study 34082839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 60
Study 34082839 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 34083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline comet assay (single cell gel electrophoresis)
Number of subjects: 19320
Study 34083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a host factor
Number of subjects: 19320
Study 34083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex and smoking habit as confounders
Number of subjects: 19320
Study 34083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to genotoxic agents
Number of subjects: 19320
Study 34083157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical radiographic contrast method using sodium iodide solution
Number of subjects: 22
Study 34083157 — intervention group
Group type: COMPARATOR
Intervention: Conventional bitewing (BW) examinations
Number of subjects: 22
Study 34083157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for classifying lesions
Number of subjects: 22
Study 34083209 — intervention group
Group type: EXPERIMENTAL
Intervention: New surveillance pathway with multimodal imaging reviewed by trained ophthalmic graders
Number of subjects: 100
Study 34083209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrawide field images
Number of subjects: 100
Study 34083209 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-field Early Treatment for Diabetic Retinopathy Study (ETDRS) images
Number of subjects: 100
Study 34083209 — intervention group
Group type: COMPARATOR
Intervention: Standard care (face-to-face evaluation by an ophthalmologist)
Number of subjects: 100
Study 34083230 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 106
Study 34083232 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 3 weeks at 2.8 mg/kg
Number of subjects: 0
Study 34083232 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 2 weeks at 2.1-3.2 mg/kg
Number of subjects: 0
Study 34083232 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 3 weeks at 0.2-3.7 mg/kg
Number of subjects: 0
Study 34083232 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 3 weeks at highest dose evaluated
Number of subjects: 0
Study 34083236 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-2029 at 4 mg/kg
Number of subjects: 45
Study 34083236 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-2029 at 5 mg/kg
Number of subjects: 45
Study 34083236 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-2029 at 4 mg/kg (expanded cohort)
Number of subjects: 45
Study 34083236 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-2029
Number of subjects: 45
Study 34083340 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBST)
Number of subjects: 158
Study 34083340 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBST) with added work ability items
Number of subjects: 158
Study 34083342 — intervention group
Group type: EXPERIMENTAL
Intervention: Social health insurance system (SHI)
Number of subjects: 7817
Study 34083342 — intervention group
Group type: COMPARATOR
Intervention: Tax-based healthcare system (THS)
Number of subjects: 7817
Study 34083342 — intervention group
Group type: EXPERIMENTAL
Intervention: Social health insurance system (SHI) in low GDP per capita settings
Number of subjects: 7817
Study 34083342 — intervention group
Group type: EXPERIMENTAL
Intervention: Social health insurance system (SHI) in low HDI settings
Number of subjects: 7817
Study 34083421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15, with surgery planned by day 29.
Number of subjects: 52